Abstract:Introduction: Previous study showed the standard dose of immunosuppressants enteric-coated mycophenolate sodium (EC-MPS) might result in unsatisfactory control rate of effective blood concentration and improvable acute rejection rate. This prospective cohort study was designed to evaluate the efficacy and safety of an intensified dosing regimen of EC-MPS in de novo kidney transplant recipients in China. Methods: This prospective cohort study enrolled patients underwent de novo renal transplantation from 2015.6 to 2018.9. Participants were divided into the intensified-dose (week 1: 2160 mg/day; week 2: 1440 mg/day; followed by 720-1080 mg/day) and standard-dose (week 1: 1440 mg/day; week 2: 1080 mg/day; followed by 720-1080 mg/day) groups. Sub-group were analyzed based on mycophenolic acid (MPA)-area under the concentration (AUC): achieved group (defined as patients whose MPA AUC is equal or beyond 40 mg.h/L within Day 7) and under exposure group (defined as patients whose MPA AUC is below 40 mg.h/L within Day 7). The primary endpoints were 12-month-biopsy-proven acute rejection (BPAR), graft and patient survival rates. safety were also assessed. The study was followed up 3 years. Results: A total of 128 patients were included, with 65 and 63 patients in the intensified-dose group and standard-dose group, respectively. The 12-month-BPAR incidence was numerically lower in the intensified-dose group than standard-dose group (4.6% vs. 9.5%, p=0.320). The rate of patients achieving target mycophenolic acid (MPA)-area under the concentration (AUC) was significantly higher in the intensified-dose group (87.5% vs. 69.8%, p=0.015) (Table 1) than standard-dose group, and patients achieving target MPA-AUC had a significantly lower 3-month-BPAR incidence (1.0% vs. 11.1%, p=0.03) (Table 2). patient and graft survival rates at 36 months between the intensified-dose and standard-dose groups was 98.5% vs. 100.0% and 98.5% vs. 100.0%, respectively. The 36-month- de novo donor-specific antibody (dnDSA) positive incidence rates was numerically lower in the intensified-dose group than standard-dose group (1.5% vs. 6.3%, p=0.204). In addition, delayed graft function, treatment failure, serum creatine levels, eGFRs and infection incidence had no significant differences between the two groups (all p>0.05) (Figure 1). The incidence rates of infection were similar in both groups (29.2% vs. 33.3%, p=0.617). No additional safety concerns related to intensified dosing of EC-MPS. Conclusion: Intensified dosing of EC-MPS results in a numerically lower incidence of 12-month-BPAR and lower positive incidence of dnDSA with 36 months follow up. Intensified dosing could help achieve target therapeutic blood concentration of EC-MPS, that showed significantly lower BPAR and no more infection incidence increased and might further improve long-term prognosis in Chinese de novo kidney transplantation recipients.

Effect of Bailing capsule on renal function of patients with chronic allograft nephropathy

[Clinical Observation on Treatment of Chronic Allograft Nephropathy with Bailing Capsule].

Intervention of Ginkgo Biloba Extract on Renal Hemodynamics and Its Clinical Protective Mechanism

Effect of Acute Cellular Rejection with C4d Deposition on Renal Allograft Survival

Use of bailing capsules (cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology

The study in the treatment of chronic allograft nephrophathy

[Acupuncture-moxibustion for chronic allograft nephropathy: a randomized controlled trial]

[Effect of total saponins of Panax notoginseng on urinary albumin in patients with chronic renal failure]

Conversion from Calcineurin Inhibitors to Sirolimus in Chronic Allograft Nephropathy: a 4-Year Prospective Study

Bailing capsule (Cordyceps sinensis) ameliorates renal triglyceride accumulation through the PPARα pathway in diabetic rats

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Clinical Analysis of 2520 Renal Transplantations in One Center

Clinical outcomes in renal allograft recipients switched to long-term immunosuppressive therapy with mycophenolate mofetil after renal transplantation

Effect of Shen Xian Kang Decoction Combined Mycophenolate Mofetil in Patients with Proliferative Sclerosing IgA Nephropathy

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Long term follow up of renal transplant recipients with borderline change

Histological Isolated Endarteritis Benefits Glomerular Filtration Rate And Allograft Survival After Anti-Rejection Treatment

Long-term effect of eplerenone treatment in children with chronic allograft nephropathy

[Effect of donor bone marrow transfusion on renal allograft function in kidney transplant patients].

Therapeutic Efficacy of Bailing Capsule for Stable COPD:Systematic Review